Shares of Alumis Inc. (NASDAQ:ALMS - Get Free Report) have been assigned a consensus rating of "Buy" from the nine research firms that are presently covering the stock, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $26.57.
A number of brokerages have recently issued reports on ALMS. Oppenheimer began coverage on shares of Alumis in a research note on Thursday, January 30th. They set an "outperform" rating and a $32.00 target price for the company. HC Wainwright restated a "buy" rating and issued a $19.00 target price on shares of Alumis in a research note on Monday, March 10th.
View Our Latest Stock Analysis on ALMS
Hedge Funds Weigh In On Alumis
Several institutional investors have recently bought and sold shares of ALMS. BNP Paribas Financial Markets purchased a new stake in Alumis during the third quarter worth $27,000. Wells Fargo & Company MN boosted its position in Alumis by 77.1% during the fourth quarter. Wells Fargo & Company MN now owns 8,779 shares of the company's stock valued at $69,000 after purchasing an additional 3,823 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Alumis in the fourth quarter valued at about $79,000. MetLife Investment Management LLC purchased a new stake in shares of Alumis during the third quarter valued at about $89,000. Finally, Marshall Wace LLP bought a new stake in shares of Alumis in the 4th quarter valued at about $108,000.
Alumis Price Performance
Shares of ALMS stock traded up $0.03 on Friday, reaching $4.51. 58,437 shares of the company's stock were exchanged, compared to its average volume of 170,658. The company's fifty day simple moving average is $5.91 and its 200 day simple moving average is $8.72. Alumis has a 52 week low of $4.25 and a 52 week high of $13.53.
About Alumis
(
Get Free ReportOur mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Featured Articles
Before you consider Alumis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.
While Alumis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
